Lawrence Paszat

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Are you Lawrence Paszat?

Claim your profile

Publications (175)928.94 Total impact

  • JAMA The Journal of the American Medical Association 12/2014; 312(21):2285-6. · 30.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Prior randomized, controlled trials (RCTs) indicate patient navigation can boost colorectal cancer (CRC) screening in primary care. The sparse literature on pragmatic trials of interventions designed to increase CRC screening adherence motivated this trial on the impact of a patient navigation intervention that included support for performance of the participants' preferred screening test (colonoscopy or stool blood testing). Methods:Primary-care patients (n = 5240), 50-74 years of age, with no prior diagnosis of bowel cancer, and no record of a recent CRC screening test were identified at the Group Health Centre in northern Ontario. These patients were randomly assigned to an Intervention Group (N = 2629) or a usual care Control Group (N = 2611). Intervention Group participants were contacted by a trained nurse navigator by telephone to discuss CRC screening. Interested patients met with the navigator, who helped them identify and arrange for performance of the preferred screening test. Multivariate analyses were conducted using medical records data to assess intervention impact on screening adherence within 12 months after randomization. Results: Mean patient age was 59 years, and 50% of participants were women. CRC screening adherence was higher in the Intervention Group (35%) compared to the Control Group (20%), a difference that was statistically significant (OR-2.11, CI: 1.87 - 2.39). Conclusions: Preference-based patient navigation increased screening uptake in a pragmatic RCT. Impact: Patient navigation increased CRC screening rates in a pragmatic RCT in proportions similar to those observed in explanatory RCTs.
    Cancer Epidemiology Biomarkers & Prevention 11/2014; · 4.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to estimate the effect of cervical screening in the prevention of invasive cervical cancer among age groups, using a population-based case-control study in the province of Ontario, Canada.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 11/2014;
  • Rachel Kupets, Yan Lu, Danielle Vicus, Lawrence Paszat
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: When cervical cytology screening shows atypical squamous cells of unknown significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL), and cervical cytology screening has not been performed in the previous year, it is recommended that cytology screening be repeated six months later. Women with persistent abnormalities should be referred for colposcopy. We explored provincial databases in Ontario to determine whether these recommendations were always followed. Methods: Cervical cytology reports in Ontario are contained in a provincial database, deterministically linkable to other health services databases, including those recording physician reimbursement claims for colposcopy. We identified all women in Ontario who had a first time diagnosis of ASCUS or LSIL in 2008 or 2009. We searched for additional cytology reports and for colposcopy billing claims during the 24 months following the date of the first abnormal report. We assessed the interaction of socioeconomic status, having abnormal cytology, and having repeat cytology after a report of low-grade abnormal cervical cytology. Results: A total of 74 770 women had a first time report of low-grade abnormal cytology. Among women with ASCUS and LSIL, 69.7% and 60.3%, respectively, underwent repeat cytology. Repeat cytology following ASCUS disclosed normal (68.2%), ASCUS (19.3%), LSIL (10.6%), and high-grade squamous intraepithelial lesion (1.4%); following LSIL, the corresponding percentages were 48.3%, 18.0%, 30.8%, and 2.6%. Of women with ASCUS, 16.2% went directly for colposcopy; 14.0% did not repeat cytology or go for colposcopy. Of women with LSIL, 26.4% went directly for colposcopy but 13.4% had no follow-up. Conclusion: We have demonstrated the potential for substantial improvement in cervical cytology six months after a finding of ASCUS and LSIL. We found that many women with ASCUS and LSIL had unnecessary referrals directly for colposcopy, and we identified a lack of follow-up for one sixth of women with low-grade abnormal cytology.
    10/2014; 36(10):892-899.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regular screening using guaiac fecal occult blood test (gFOBT) reduces mortality from colorectal cancer (CRC). The objective of this study was to determine whether the addition of a gFOBT kit to a 2nd mailed invitation compared to a 2nd mailed invitation alone increases CRC screening among eligible persons who did not respond to an initial mailed invitation. We conducted a cluster randomized controlled trial, with the physician as the unit of randomization. Participants were persons who had been invited but who had not responded to an invitation for CRC screening in an earlier pilot project. The intervention group received a mailed gFOBT kit and 2nd mailed CRC screening invitation (n=2008) while the control group received a 2nd mailed CRC screening invitation alone (n=1586). The primary outcome was the uptake of gFOBT within 6 months of the 2nd mailing. We found that the uptake of gFOBT was more than twice as high in the intervention group (20.1%) compared to the control group (9.6%). The absolute difference between the 2 groups was 10.5% (95% CI: 7.5 – 13.4%, p=<0.0001). In a subsequent adjusted analysis, participants in the intervention group were twice as likely to complete the test as those in the control group (OR=2.1; 95% CI: 1.6-2.6). These findings suggest that directly mailed gFOBT kits increases CRC screening participation among previous non-responders to a mailed invitation and that approximately 10 gFOBT kits would have to be sent by mail in order to screen 1 additional person. ( NCT01629004). © 2014 Wiley Periodicals, Inc.
    International Journal of Cancer 09/2014; · 6.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Whole-breast radiation therapy (XRT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) may decrease the risk of local recurrence, but the optimal dose regimen remains unclear. Past studies administered 50 Gy in 25 fractions (conventional); however, treatment pattern studies report that hypofractionated (HF) regimens (42.4 Gy in 16 fractions) are frequently used. We report the impact of HF (vs conventional) on the risk of local recurrence after BCS for DCIS. Methods and Materials All women with DCIS treated with BCS and XRT in Ontario, Canada from 1994 to 2003 were identified. Treatment and outcomes were assessed through administrative databases and validated by chart review. Survival analyses were performed. To account for systematic differences between women treated with alternate regimens, we used a propensity score adjustment approach. Results We identified 1609 women, of whom 971 (60%) received conventional regimens and 638 (40%) received HF. A total of 489 patients (30%) received a boost dose, of whom 143 (15%) received conventional radiation therapy and 346 (54%) received HF. The median follow-up time was 9.2 years. The median age at diagnosis was 56 years (interquartile range [IQR], 49-65 years). On univariate analyses, the 10-year actuarial local recurrence–free survival was 86% for conventional radiation therapy and 89% for HF (P=.03). On multivariable analyses, age <45 years (hazard ratio [HR] = 2.4; 95% CI: 1.6-3.4; P<.0001), high (HR=2.9; 95% CI: 1.2-7.3; P=.02) or intermediate nuclear grade (HR=2.7; 95% CI: 1.1-6.6; P=.04), and positive resection margins (HR=1.4; 95% CI: 1.0-2.1; P=.05) were associated with an increased risk of local recurrence. HF was not significantly associated with an increased risk of local recurrence compared with conventional radiation therapy on multivariate analysis (HR=0.8; 95% CI: 0.5-1.2; P=.34). Conclusions The risk of local recurrence among individuals treated with HF regimens after BCS for DCIS was similar to that among individuals treated with conventional radiation therapy.
    International journal of radiation oncology, biology, physics 09/2014; · 4.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the publication of two randomized controlled trials (RCT) in 1996 demonstrating the effectiveness of fecal occult blood test (FOBT) in reducing colorectal cancer (CRC) mortality, several public health initiatives have been introduced in Ontario to promote FOBT participation. We examined the effect of these initiatives on FOBT participation and evaluated temporal trends in participation between 1994 and 2012.
    BMC Cancer 07/2014; 14(1):537. · 3.32 Impact Factor
  • Canadian journal of gastroenterology & hepatology. 07/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES:The sessile serrated adenoma/polyp (SSA/P) is increasingly recognized as an important precursor to colorectal cancer (CRC) and may contribute to proximal postcolonoscopy CRCs. Hyperplastic polyps (HPs) generally follow a more benign course than do SSA/Ps, but they have a similar histologic appearance. Our aims were to identify patient and polyp factors associated with reclassification of HPs as SSA/Ps during a central pathology review and to characterize and compare their subsequent clinical management with other polyps.METHODS:From 2003 to 2008, we prospectively enrolled asymptomatic persons aged 50-74 years in a study of screening colonoscopy. Because criteria for SSA/P diagnosis evolved over our study period, we initiated a second review of all HPs >5 mm in size in 2011, with reclassification of polyps if indicated. Rates of subsequent colonoscopies, polypectomies, and CRCs were identified.RESULTS:We enrolled 2,527 persons who underwent colonoscopy in whom 111 had HPs >5 mm. Thirty-two of the 111 participants (28.8%) with HPs >5 mm had their polyps reclassified as SSA/Ps. There were no significant differences in patient characteristics between those with reclassified SSA/Ps and those who had HPs >5 mm. SSA/Ps were more likely to be proximal (P<0.001) and larger (P<0.007) than the HPs. In all, 48.3% of those with high-risk adenomas received appropriate follow-up compared with 26.1% of those with high-risk SSA/Ps.CONCLUSIONS:Almost 1/3 of recently diagnosed HPs >5 mm were reclassified as SSA/Ps. Patients previously diagnosed with larger HPs in the proximal colon may benefit from a pathologic review to ensure appropriate diagnosis and follow-up.Am J Gastroenterol advance online publication, 8 July 2014; doi:10.1038/ajg.2014.78.
    The American Journal of Gastroenterology 07/2014; · 9.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is limited evidence for the effectiveness of pay for performance despite its widespread use. We assessed whether the introduction of a pay-for-performance scheme for primary care physicians in Ontario, Canada, was associated with increased cancer screening rates and determined the amounts paid to physicians as part of the program.
    The Annals of Family Medicine 07/2014; 12(4):317-23. · 4.57 Impact Factor
  • Gastrointestinal Endoscopy 05/2014; 79(5):AB118. · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To estimate the effect of cervical cancer screening on mortality from cervical cancer in women between the age of 20 to 69 residing in Ontario by 5 year age groups. Methods An Ontario population based case–control study of women between age 20 to 69 was performed. Cases were women who were diagnosed with cervical cancer between January 1,1998 and December 31,2008 who died from cervical cancer within this period. Controls were women without a diagnosis of cervical cancer between January 1,1998 and December 31,2008 who were alive on the case’s date of death. Exposure was defined as cervical cytology history. Conditional logistic regression was used to estimate the strength of association between mortality from cervical cancer and screening in 5 year incremental age intervals. Results We identified 1,052 cases and 10,494 controls. Less than 2.5% of women who died from cervical cancer were under the age of 30. Cervical cancer screening performed 3–36 months prior to the date of diagnosis was found to be protective of mortality from cervical cancer in women over the age of 30(odds ratio = 0.28-0.60;p < 0.05 in all strata). In women under the age of 30 cervical cancer screening was not found to be protective of mortality from cervical cancer(odds ratio = 1.58-2.43;non significant). Conclusion No association between cervical cancer screening and mortality from cervical cancer under the age of 30 was found. This could be due to there being a small or no effect or due to the fact that mortality from cervical cancer under the age of 30 is extremely rare.
    Gynecologic Oncology 05/2014; · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Estimating risk for advanced proximal neoplasia (APN) based on distal colon findings can help identify asymptomatic persons who should undergo examination of the proximal colon after flexible sigmoidoscopy (FS) screening. We aimed to determine the risk of APN by most advanced distal finding among an average-risk screening population. Prospective, cross-sectional study. Teaching hospital and colorectal cancer screening center. A total of 4651 asymptomatic persons at average risk for colorectal cancer aged 50 to 74 years (54.4% women [n = 2529] with a mean [± standard deviation] age of 58.4 ± 6.2 years). All participants underwent a complete colonoscopy, including endoscopic removal of all polyps. We explored associations between several risk factors and APN. Logistic regression was used to identify independent predictors of APN. A total of 142 persons (3.1%) had APN, of whom 85 (1.8%) had isolated APN (with no distal findings). APN was associated with older age, a BMI >27 kg/m(2), smoking, distal advanced adenoma and/or cancer, and distal non-advanced tubular adenoma. Those with a distal advanced neoplasm were more than twice as likely to have APN compared with those without distal lesions. Distal findings used to estimate risk of APN were derived from colonoscopy rather than FS itself. In persons at average risk for colorectal cancer, the prevalence of isolated APN was low (1.8%). Use of distal findings to predict APN may not be the most effective strategy. However, incorporating factors such as age (>65 years), sex, BMI (>27 kg/m(2)), and smoking status, in addition to distal findings, should be considered for tailoring colonoscopy recommendations. Further evaluation of risk stratification approaches in other asymptomatic screening populations is warranted.
    Gastrointestinal endoscopy 03/2014; · 4.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A central tenet of organised cancer screening is that all persons in a target population are invited. The aims of this study were to identify participant and physician factors associated with response to mailed physician-linked invitations (study 1) and to evaluate their effectiveness in an organised colorectal cancer (CRC) screening programme (study 2). 2 studies (study 1-cohort design and study 2-matched cohort design, comprising study 1 participants and a matched control group) were conducted in the context of Ontario's organised province-wide CRC screening programme. 102 family physicians and 11 302 associated eligible patients from a technical evaluation ('the Pilot') of large-scale mailed invitations for CRC screening were included. Matched controls were randomly selected using propensity scores from among eligible patients associated with family physicians in similar practice types as the Pilot physicians. Physician-linked mailed invitation to have CRC screening. Uptake of faecal occult blood test (FOBT) within 6 months of mailed invitation (primary) and uptake of FOBT or colonoscopy within 6 months of mailed invitation (secondary). Factors significantly associated with uptake of FOBT included prior FOBT use, older participant age, greater participant comorbidity and having a female physician. In the matched analysis, Pilot participants were more likely to complete an FOBT (22% vs 8%, p<0.0001) or an FOBT or colonoscopy (25% vs 11%, p<0.0001) within 6 months of mailed invitation than matched controls. The number needed to invite to screen one additional person was 7. Centralised large-scale mailing of physician-linked invitations is feasible and effective in the context of organised CRC screening.
    BMJ Open 03/2014; 4(3):e004494. · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The main goal of treating ductal carcinoma in situ (dcis) is to prevent the development of invasive breast cancer. Most women are treated with breast-conserving surgery (bcs) and radiotherapy. Age at diagnosis may be a risk factor for recurrence, leading to concerns that additional treatment may be necessary for younger women. We report a population-based study of women with dcis treated with bcs and radiotherapy and an evaluation of the effect of age on local recurrence (lr). All women diagnosed with dcis in Ontario from 1994 to 2003 were identified. Treatments and outcomes were collected through administrative databases and validated by chart review. Women treated with bcs and radiotherapy were included. Survival analyses were performed to evaluate the effect of age on outcomes. We identified 5752 cases of dcis; 1607 women received bcs and radiotherapy. The median follow-up was 10.0 years. The 10-year cumulative lr rate was 27% for women younger than 45 years, 14% for women 45-50 years, and 11% for women more than 50 years of age (p < 0.0001). The 10-year cumulative invasive lr rate was 22% for women younger than 45 years, 10% for women 45-50 years, and 7% for women more than 50 years of age (p < 0.0001). On multivariate analyses, young age (<45 years) was significantly associated with lr and invasive lr [hazard ratio (hr) for lr: 2.6; 95% confidence interval (ci): 1.9 to 3.7; p < 0.0001; hr for invasive lr: 3.0; 95% ci: 2.0 to 4.4; p < 0.0001]. An age of 45-50 years was also significantly associated with invasive lr (hr: 1.6; 95% ci: 1.0 to 2.4; p = 0.04). Age at diagnosis is a strong predictor of lr in women with dcis after treatment with bcs and radiotherapy.
    Current Oncology 02/2014; 21(1):e96-e104. · 1.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: ColonCancerCheck (CCC), Canada's first province-wide colorectal cancer (CRC) screening program, was publicly launched in Ontario in April 2008. The objective of this paper is to report on key indicators of CCC Program performance since its inception. Methods: The CCC Program recommends biennial gFOBT for persons 50 to 74 years of age at average risk for CRC and colonoscopy for those at increased risk. Opportunistic screening with colonoscopy is available in Ontario. Five data sources were used to compute indicators of program performance during 2008-11. The indicators computed were FOBT participation, overdue for screening, FOBT positivity, positive predictive value (PPV) of FOBT for CRC, diagnostic follow-up, and CRC detection rate. Results: In 2011, FOBT participation was 29.8% and 46.8% of the target population was overdue for screening. FOBT positivity was higher among men (5.1%) than women (3.5%), and the PPV of FOBT for cancer was 4.3% in 2011. Follow-up colonoscopy within six months of a positive FOBT was completed by 74.6% of Program participants in 2011. The cancer detection rates for FOBT and for colonoscopy in those with a family history were 1.3 per 1,000 and 4.0 per 1,000, respectively, in 2011. Conclusions: These results provide an early indication of Program performance and provide findings relevant to other organized CRC screening programs. Impact: The greater cancer detection rate in those at increased risk due to family history who undergo colonoscopy screening suggests that a strategy of risk stratification will enhance the impact of FOBT-based screening programs.
    Cancer Epidemiology Biomarkers & Prevention 01/2014; · 4.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The approach for staging gastric adenocarcinoma (GC) has not been well defined, with heterogeneity in the application of staging modalities. Methods Utilizing a RAND/UCLA appropriateness methodology (RAM), a multidisciplinary expert panel of 16 physicians scored 84 GC staging scenarios. Appropriateness was scored from 1 to 9. Median appropriateness scores from 1 to 3 were considered inappropriate, 4–6 uncertain, and 7–9 appropriate. Agreement was reached when 12 or more of 16 panelists scored the scenario similarly. Appropriate scenarios were subsequently scored for necessity. Results Pretreatment TNM stage determination is necessary. Necessary staging maneuvers include esophagogastroduodenoscopy (EGD); biopsy of the tumor; documentation of tumor size, description, location, distance from gastroesophageal junction (GEJ), and any GEJ, esophageal, or duodenal involvement; if an EGD report is unclear, surgeons should repeat it to confirm tumor location. Pretreatment radiologic assessment should include computed tomography (CT)-abdomen and CT-pelvis, performed with multidetector CT scanners with 5-mm slices. Laparoscopy should be performed before resection of cT3–cT4 lesions or multivisceral resections. Laparoscopy should include inspection of the stomach, diaphragm, liver, and ovaries. Conclusions Using a RAM, we describe appropriate and necessary staging tests for the pretreatment staging evaluation of GC, as well as how some of these staging maneuvers should be conducted.
    Gastric Cancer 01/2014; · 4.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To describe the perceptions of those who received invitations to the ColonCancerCheck Primary Care Invitation Pilot (the Pilot) about the mailed invitation, colorectal cancer (CRC) screening in general, and their specific screening experiences. Qualitative study with 6 focus group sessions, each 1.5 hours in length. Hamilton, Ont; Ottawa, Ont; and Thunder Bay, Ont. Screening-eligible adults, aged 50 years and older, who received a Pilot invitation for CRC screening. The focus groups were conducted by a trained moderator and were audiorecorded and transcribed verbatim. The transcripts were analyzed using grounded-theory techniques facilitated by the use of electronic software. Key themes related to the invitation letter, the role of the family physician, direct mailing of the fecal occult blood testing (FOBT) kit, and alternate CRC screening promotion strategies were identified. Specifically, participants suggested the letter content should use stronger, more powerful language to capture the reader's attention. The importance of the family physician was endorsed, although participants favoured clarification of the physician and program roles in the actual mailed invitation. Participants expressed support for directly mailing FOBT kits to individuals, particularly those with successful previous test completion, and for communication of both negative and positive screening results. This study yielded a number of important findings including strategies to optimize letter content, support for directly mailed FOBT kits, and strategies to report results that might be highly relevant to other health programs where population-based CRC screening is being considered.
    Canadian family physician Medecin de famille canadien 12/2013; 59(12):e541-e549. · 1.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IMPORTANCE There is growing interest in reducing the variations and deficiencies in the multidisciplinary management of gastric cancer. OBJECTIVE To define optimal treatment strategies for gastric adenocarcinoma (GC). DESIGN, SETTING, AND PARTICIPANTS RAND/UCLA Appropriateness Method involving a multidisciplinary expert panel of 16 physicians from 6 countries. INTERVENTIONS Gastrectomy, perioperative chemotherapy, adjuvant chemoradiation, surveillance endoscopy, and best supportive care. MAIN OUTCOMES AND MEASURES Panelists scored 416 scenarios regarding treatment scenarios for appropriateness from 1 (highly inappropriate) to 9 (highly appropriate). Median appropriateness scores from 1 to 3 were considered inappropriate; 4 to 6, uncertain; and 7 to 9, appropriate. Agreement was reached when 12 of 16 panelists scored the scenario similarly. Appropriate scenarios agreed on were subsequently scored for necessity. RESULTS For patients with T1N0 disease, surgery alone was considered appropriate, while there was no agreement over surgery alone for patients T2N0 disease. Perioperative chemotherapy was appropriate for patients who had T1-2N2-3 or T3-4 GC without major symptoms. Adjuvant chemoradiotherapy was classified as appropriate for T1-2N1-3 or T3-4 proximal GC and necessary for T1-2N2-3 or T3-4 distal GC. There was no agreement regarding surveillance imaging and endoscopy following gastrectomy. Surveillance endoscopy was deemed to be appropriate after endoscopic resection. For patients with metastatic GC, surgical resection was considered inappropriate for those with no major symptoms, unless the disease was limited to positive cytology alone, in which case there was disagreement. CONCLUSIONS AND RELEVANCE Patients with GC being treated with curative intent should be considered for multimodal treatment. For patients with incurable disease, surgical interventions should be considered only for the management of major bleeding or obstruction.
    JAMA surgery. 11/2013;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The utility of post mastectomy radiotherapy in very young women is understudied. The objective of this study was to evaluate the use of PMRT in very young women to determine the effect on recurrence and survival. All women aged ≤35 years diagnosed with invasive breast cancer from 1994 to 2003 were identified from the Ontario Cancer Registry. Patient, tumour, treatment and outcome data were abstracted from primary chart review. Local or regional recurrence was the primary endpoint with contralateral, distant recurrence/death treated as competing risks. Propensity score methods were incorporated into multivariable Cox proportional hazards models to evaluate the effect of radiation therapy on the time to local/regional, distant recurrence or death. 588 patients were identified during the study period, of which 382 were eligible for analysis. Overall, 182 (48 %) of patients sustained a recurrence after a median follow-up of 2.72 years. The use of PMRT significantly reduced locoregional recurrence (HR 0.54, 95 % CI 0.29-0.996) compared with those who did not receive PMRT. There was no significant effect of PMRT on contralateral, distant recurrences, or death without recurrence (HR 0.98, 95 % CI 0.66-1.47). Of the patients with known node status (N = 451), isolated local recurrence occurred in 5, 2.5, and 8.5 % in patients with N0, N1-3, and N4 positive nodes respectively. We have found a significant reduction in locoregional recurrence with PMRT but no survival benefit in very young women with breast cancer.
    Annals of Surgical Oncology 10/2013; · 3.94 Impact Factor

Publication Stats

4k Citations
928.94 Total Impact Points


  • 2006–2014
    • Sunnybrook Health Sciences Centre
      • • Department of Radiation Oncology
      • • Department of Medicine
      Toronto, Ontario, Canada
  • 2003–2014
    • Institute for Clinical Evaluative Sciences
      Toronto, Ontario, Canada
    • Cancer Care Ontario
      Toronto, Ontario, Canada
  • 2001–2014
    • University of Toronto
      • • Institute of Health Policy, Management and Evaluation
      • • Department of Surgery
      • • Department of Radiation Oncology
      • • Department of Medicine
      • • Institute for Clinical Evaluative Sciences
      Toronto, Ontario, Canada
  • 2013
    • Women's College Hospital
      Toronto, Ontario, Canada
    • Chinook Regional Hospital
      Lethbridge, Alberta, Canada
    • Maimonides Medical Center
      Brooklyn, New York, United States
  • 2009–2012
    • University Health Network
      • Department of Medicine
      Toronto, Ontario, Canada
    • University of British Columbia - Vancouver
      • Division of Gynaecologic Oncology
      Vancouver, British Columbia, Canada
  • 2011
    • The University of Calgary
      Calgary, Alberta, Canada
  • 1998–2008
    • Regional Integration Cancer Center
      Мендоса, Mendoza, Argentina
  • 2007
    • Dalhousie University
      Halifax, Nova Scotia, Canada
    • The University of Western Ontario
      London, Ontario, Canada
    • University of Texas MD Anderson Cancer Center
      • Department of Gynecologic Oncology
      Houston, TX, United States
  • 2006–2007
    • McMaster University
      • Department of Obstetrics and Gynaecology
      Hamilton, Ontario, Canada
  • 2003–2005
    • The Princess Margaret Hospital
      Toronto, Ontario, Canada
  • 1997–2002
    • Queen's University
      • Department of Oncology
      Kingston, Ontario, Canada
  • 2000
    • Kingston General Hospital
      Kingston, Ontario, Canada